Prior lines of therapy for all patients with ITP who received azathioprine
| Patients who received azathioprine (N = 92) . | n (%) . |
|---|---|
| No. of prior lines of therapy, median (range) | 2 (1-6) |
| 1 line | 22 (23.9%) |
| 2 lines | 31 (33.7%) |
| 3 lines | 26 (28.3%) |
| 4 lines | 9 (9.8%) |
| 5 lines | 3 (3.3%) |
| 6 lines | 1 (1.1%) |
| Individual treatments received before azathioprine | |
| Corticosteroids | 92 (100.0%) |
| IVIG | 54 (58.7%) |
| Rituximab | 22 (23.9%) |
| Splenectomy | 27 (29.3%) |
| TPO-RA | 6 (6.5%) |
| Other immunosuppressive drugs∗ | 17 (18.5%) |
| Patients who received azathioprine (N = 92) . | n (%) . |
|---|---|
| No. of prior lines of therapy, median (range) | 2 (1-6) |
| 1 line | 22 (23.9%) |
| 2 lines | 31 (33.7%) |
| 3 lines | 26 (28.3%) |
| 4 lines | 9 (9.8%) |
| 5 lines | 3 (3.3%) |
| 6 lines | 1 (1.1%) |
| Individual treatments received before azathioprine | |
| Corticosteroids | 92 (100.0%) |
| IVIG | 54 (58.7%) |
| Rituximab | 22 (23.9%) |
| Splenectomy | 27 (29.3%) |
| TPO-RA | 6 (6.5%) |
| Other immunosuppressive drugs∗ | 17 (18.5%) |
IVIG, IV immunoglobulin.
Includes danazol, mycophenolate mofetil, hydroxychloroquine, and cyclophosphamide, etc.